Baltimore, Maryland – Rapid is pleased to announce that it has received FDA 510(k) market clearance for its first software product: 3D-RD-S, the first web-browser based application that implements the MIRD Schema to perform radiopharmaceutical dosimetry calculations. It is based on the most recent ICRP phantoms and data, supports 1,252... Learn More
Shielding NorthStar's first pair of IBA Rhodotron® accelerators - a first-of-its-kind radioisotope facility. June 27, 2022 11:00 ET | Source: Veritas Medical Solutions... HARLEYSVILLE, Pa., June 27, 2022 (GLOBE NEWSWIRE) -- As part of its expansion of radiation shielding solutions in the Industrial segment for radiopharmaceutical... Learn More
February 14th, 2023 FOR IMMEDIATE RELEASE Media Contact: Jamie Smith Ameriflight, LLC Director of Corporate Communications jsmith@ameriflight.com | 972.426.3066 ext. 76273
Learn More
January 26th, 2023 FOR IMMEDIATE RELEASE Media Contact: Jamie Smith Ameriflight, LLC Director of Corporate Communications jsmith@ameriflight.com | 972.426.3066 ext. 76273
Saab 340B with digital rendering of Ameriflight livery
https://www.youtube.com/watch?v=yUtfcOwfo1U ZTI BIOSCIENCES, Next Generation Radiopharmaceuticals Developer, wins the final award for U-CONNECT 2021 ... Learn More
https://www.youtube.com/watch?v=Sni8cyKkPo4 [MBN] ZTI BIOSCIENCES Targeted Radiopharmaceuticals: Next generation cancer therapy ZTI BIOSCIENCES was introduced at a national Korean economics broadcaster. ... Learn More
https://www.youtube.com/watch?v=f_5k8QiHGWo YTN, an official major broadcaster in Korea had an exclusive interview with ZTI BIOSCIENCES, the national leader in radiopharmaceuticals. Dr. Jaden H. Chang, CEO of ZTI BIOSCIENCES explains the nature of Radio Ligand Therapy. CTO Dr. Eugene Park explains ZTI's basic tech. ... Learn More
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma... Learn More
Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (¹⁸⁶Re) Obisbemeda for the Treatment of Leptomeningeal Metastases... Learn More
GenesisCare, Radiopharm Theranostics Partner to Bring World-First Novel Radiopharmaceuticals to Australian Cancer Patients